Non-alcoholic Fatty Liver Diseases (NAFLD) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
Am J Chin Med. 2024 Apr 1:1-40. doi: 10.1142/S0192415X24500149. Online ahead of print.ABSTRACTLiver diseases and their related complications endanger the health of millions of people worldwide. The prevention and treatment of liver diseases are still serious challenges both in China and globally. With the improvement of living standards, the prevalence of metabolic liver diseases, including non-alcoholic fatty liver disease and alcoholic liver disease, has increased at an alarming rate, resulting in more cases of end-stage liver disease. Therefore, the discovery of novel therapeutic drugs for the treatment of liver disease...
Source: The American Journal of Chinese Medicine - March 30, 2024 Category: Complementary Medicine Authors: Yu Mou Wenhao Liao Yuchen Li Lina Wan Jingwen Liu Xialing Luo Hongping Shen Qin Sun Jing Wang Jianyuan Tang Zhilei Wang Source Type: research

Letter Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 30, 2024 Category: Cancer & Oncology Authors: Xiangyi Dai, Chonglin Liu, Wei Li, Xiaojun Ma, Kaiping Jiang Tags: Letter to the Editor Source Type: research

Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
Based on the rapidly growing global burden of non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), in order to evaluate the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the treatment of NAFLD or NASH this paper presents a systematic review and meta-analysis of randomized controlled trials(RCTs). (Source: Primary Care Diabetes)
Source: Primary Care Diabetes - March 30, 2024 Category: Primary Care Authors: Lixuan Fang, Jine Li, Haixia Zeng, Jianping Liu Source Type: research

A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials
ConclusionWe summarised the landscape of current clinical trials and suggested the directions for future NAFLD therapy to assist internal medicine specialists in treating the whole clinical spectrum of this highly prevalent liver disease. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 29, 2024 Category: Endocrinology Source Type: research

The MASLD criteria overlook a number of adolescent patients with severe steatosis
We read with a great interest the consensus statement on the proposed new fatty liver disease nomenclature to replace non-alcohol fatty liver disease (NAFLD) with metabolic dysfunction-associated steatotic liver disease (MASLD) and diagnostic criteria for diagnosing MASLD in children and adolescents 1. These criteria are similar (although not identical) to the diagnostic criteria of the metabolic dysfunction –associated fatty liver disease (MAFLD), which was the first definition to provide a set of positive diagnostic criteria that acknowledge that fatty liver is a continuum across the lifespan 2-4. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 29, 2024 Category: Gastroenterology Authors: Ziyan Pan, Mohammed Eslam, panel of collaborators Tags: Letter to the Editor Source Type: research

Deletion of Mixed Lineage Kinase Domain Like Pseudokinase Aggravates Chronic Alcohol-Induced Liver Injury via Increasing Apoptosis
ConclusionMLKL deletion did not prevent chronic alcohol-induced liver damage independently of necroptosis and exacerbated hepatic steatosis by increasing hepatocyte apoptosis.Graphical Abstract (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - March 29, 2024 Category: Gastroenterology Source Type: research

The effects of high-intensity interval training and Iranian propolis extract on serum levels of TRPV4 and CYP2E1 proteins in patients with nonalcoholic fatty liver
CONCLUSION: HIIT and propolis supplementation can be used to reduce TRPV4 and CYP2E1, which in turn reduces oxidative stress and inflammation in patients with NAFLD.PMID:38545725 | DOI:10.62438/tunismed.v102i1.4669 (Source: Cancer Control)
Source: Cancer Control - March 28, 2024 Category: Cancer & Oncology Authors: Khadijeh Irandoust Mahsa Gholamhosseini Rasool Samimi Ismail Dergaa Helmi Ben Saad Mortez Taheri Source Type: research

Clinical Features and Long-Term Outcomes of Patients Diagnosed with MASLD, MAFLD, or Both
We read with great interest the recently reported work regarding clinical profiles for metabolic dysfunction-associated steatotic liver disease (MASLD) and non-alcoholic fatty liver disease (NAFLD) by Younossi 1. Metabolic dysfunction-associated fatty liver disease (MAFLD) and MASLD were introduced as new terminologies to address the limitations associated with NAFLD 2,3. MASLD encompasses patients with at least one of five cardiometabolic risk factors and captures more lean patients than MAFLD. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 28, 2024 Category: Gastroenterology Authors: Xiao-Dong Zhou, Amedeo Lonardo, Calvin Q. Pan, Michael D. Shapiro, Ming-Hua Zheng, WMU MAFLD Clinical Research Working Group Tags: Letter to the Editor Source Type: research

Response to letter entitled: Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 28, 2024 Category: Cancer & Oncology Authors: James A. Thomas, Bradley J. Kendall, Graeme A. Macdonald, Aaron P. Thrift Source Type: research

A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials
ConclusionWe summarised the landscape of current clinical trials and suggested the directions for future NAFLD therapy to assist internal medicine specialists in treating the whole clinical spectrum of this highly prevalent liver disease. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 27, 2024 Category: Endocrinology Source Type: research

GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
Curr Pharm Des. 2024;30(2):100-114. doi: 10.2174/0113816128283153231226103218.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) has recently emerged as a global public health concern. Currently, the cornerstone of NAFLD treatment is lifestyle modification and, if necessary, weight loss. However, compliance is a challenge, and this approach alone may not be sufficient to halt and treat the more serious disease development, so medication is urgently needed. Nevertheless, no medicines are approved to treat NAFLD. Glucagon-like peptide-1 (GLP-1) is an enteropeptide hormone that inhibits glucagon synthesis, promotes insulin sec...
Source: Current Pharmaceutical Design - March 27, 2024 Category: Drugs & Pharmacology Authors: Haoran Jiang Linquan Zang Source Type: research

Trimethylamine-N-oxide, a New Risk Factor for Non-alcoholic Fatty Liver Disease Changes the Expression of miRNA-34a, and miRNA-122 in the Fatty Liver Cell Model
This study investigated the expression of miRNA-34a, miRNA-122, and miRNA-192 in the fatty liver cell model treated with different concentrations of TMAO. A fatty liver cell model was developed by exposing HepG2 cells to a mixture of palmitate and oleate in a ratio of 1:2 at a final concentration of 1200 μM for 24 h. The confirmed fatty liver cells were treated with 37.5, 75, 150, and 300 μM of TMAO for 24 h. RT-qPCR was used to quantify the expression of microRNAs in a cellular model. The cellular expression of all microRNAs was significantly higher in treated fatty liver cells compared to normal HepG2 cells (P < 0.0...
Source: Biochemical Genetics - March 27, 2024 Category: Genetics & Stem Cells Authors: Zhila Bahramirad Mohammad Raman Moloudi Mohammad Moradzad Alina Abdollahi Zakaria Vahabzadeh Source Type: research

Identification of diagnostic gene signatures and molecular mechanisms for non-alcoholic fatty liver disease and Alzheimer's disease through machine learning algorithms
CONCLUSION: This study highlights GADD45G and NUPR1 as key biomarkers for NAFLD and AD, and provides novel insights into their molecular connections. These findings revealed potential therapeutic targets, particularly in macrophage-mediated pathways, thus enriching our understanding of these complex diseases.PMID:38537674 | DOI:10.1016/j.cca.2024.117892 (Source: International Journal of Clinical Chemistry)
Source: International Journal of Clinical Chemistry - March 27, 2024 Category: Chemistry Authors: Liqing Jiang Qian Wang Yingsong Jiang Dadi Peng Kezhen Zong Shan Li Wenyuan Xie Cheng Zhang Kaili Li Zhongjun Wu Zuotian Huang Source Type: research

Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases
Curr Issues Mol Biol. 2024 Mar 11;46(3):2320-2342. doi: 10.3390/cimb46030148.ABSTRACTRare ginsenoside compound K (CK) is an intestinal microbial metabolite with a low natural abundance that is primarily produced by physicochemical processing, side chain modification, or metabolic transformation in the gut. Moreover, CK exhibits potent biological activity compared to primary ginsenosides, which has raised concerns in the field of ginseng research and development, as well as ginsenoside-related dietary supplements and natural products. Ginsenosides Rb1, Rb2, and Rc are generally used as a substrate to generate CK via several...
Source: Current Issues in Molecular Biology - March 27, 2024 Category: Molecular Biology Authors: Md Niaj Morshed Reshmi Akter Md Rezaul Karim Safia Iqbal Se Chan Kang Deok Chun Yang Source Type: research